BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28975382)

  • 1. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
    Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
    Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
    Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
    Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT.
    Główka F; Kasprzyk A; Romański M; Wróbel T; Wachowiak J; Szpecht D; Kałwak K; Wiela-Hojeńska A; Dziatkiewicz P; Teżyk A; Żaba C
    Eur J Pharm Sci; 2015 Feb; 68():87-93. PubMed ID: 25527118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Mohanan E; Panetta JC; Lakshmi KM; Edison ES; Korula A; Na F; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Balasubramanian P
    Clin Pharmacol Ther; 2018 Sep; 104(3):575-583. PubMed ID: 29247522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation Rate-Limited Pharmacokinetics of Biologically Active Epoxy Transformers of Prodrug Treosulfan.
    Romański M; Kasprzyk A; Karbownik A; Szałek E; Główka FK
    J Pharm Sci; 2016 May; 105(5):1790-1797. PubMed ID: 27044946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance.
    Romański M; Kasprzyk A; Walczak M; Ziółkowska A; Główka F
    Eur J Pharm Sci; 2017 Nov; 109():616-623. PubMed ID: 28916482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
    Główka FK; Romański M; Wachowiak J
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
    Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
    van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
    Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
    Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
    Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sampling strategy for predicting busulfan exposure in hematopoietic stem cell transplantation recipients.
    Huang JJ; Chen B; Hu J; Yang WH
    Int J Clin Pharm; 2017 Aug; 39(4):662-668. PubMed ID: 28555420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.
    Romański M; Wachowiak J; Główka FK
    Clin Pharmacokinet; 2018 Oct; 57(10):1255-1265. PubMed ID: 29557088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation.
    Główka FK; Łada MK; Grund G; Wachowiak J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):569-74. PubMed ID: 17210272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
    Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
    Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.